Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Ldl Placebo'

Ldl Placebo published presentations and documents on DocSlides.

Trial Design Evolocumab SC

Trial Design Evolocumab SC

  • danika-pritchard
  • 0 Slides

140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...

ODYSSEY FH I and II In FH I:

ODYSSEY FH I and II In FH I:

  • Aquamarine
  • 1 Slides

From baseline to 24 weeks, the change in . LDL-C: ...

Abnormalities of LDL metabolism

Abnormalities of LDL metabolism

  • briana-ranney
  • 24 Slides

Physiology, pathophysiology and treatments. Under...

Is lower better? LDL targets and beyond.

Is lower better? LDL targets and beyond.

  • trish-goza
  • 0 Slides

Implications of the relationship between risk fac...

Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?

Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?

  • min-jolicoeur
  • 0 Slides

NICE –CG 181 Continuum of CVD Risk and its trea...

Is lower better? LDL targets and beyond.

Is lower better? LDL targets and beyond.

  • olivia-moreira
  • 0 Slides

Implications of the relationship between risk fac...

LDL Apheresis in Drug Resistant Nephrotic Syndrome

LDL Apheresis in Drug Resistant Nephrotic Syndrome

  • obrien
  • 13 Slides

Rodney D Gilbert. Patient JM. 14 year old girl, pr...

LDL is causal of atherosclerosis

LDL is causal of atherosclerosis

  • morgan
  • 17 Slides

Evidence from . meta-analyses of . Mendelian. . r...

LDL-CHOLESTEROL Presented By

LDL-CHOLESTEROL Presented By

  • williams
  • 12 Slides

Assist.Lecturer. Aseel. . Ghassan. . Daoud. M.Sc...

PCSK9 Inhibition: LDL Lowering

PCSK9 Inhibition: LDL Lowering

  • SweetiePie
  • 127 Slides

PCSK9 inhibitors. New option for dyslipidemia. Ali...

Lifestyle Tips to Lower Your LDL Cholesterol

Lifestyle Tips to Lower Your LDL Cholesterol

  • dandy
  • 1 Slides

Advice f rom the National Lipid Association Clini...

Residual risk: Is LDL target enough?

Residual risk: Is LDL target enough?

  • candy
  • 55 Slides

An interpretation of the continuous relationship b...

Novel therapies for the prevention of atherosclerotic vascu

Novel therapies for the prevention of atherosclerotic vascu

  • debby-jeon
  • 36 Slides

Prof. . John . Kastelein. Academic Medical Centre...

Protecting the heart and the kidney:

Protecting the heart and the kidney:

  • marina-yarberry
  • 38 Slides

Implications from the SHARP trial. Dr. Christina ...

Cholesterol Treatment Trialists’ (CTT) Collaboration

Cholesterol Treatment Trialists’ (CTT) Collaboration

  • briana-ranney
  • 0 Slides

Slide deck. CTT Collaboration: Background*. Histo...

FOURIER F urther cardiovascular

FOURIER F urther cardiovascular

  • trish-goza
  • 0 Slides

OU. tcomes. . R. esearch with PCSK9 . I. nhibiti...

Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in

Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in

  • pamella-moone
  • 0 Slides

Hyperlipidemic. Subjects: A 52 Week Phase 3 Dou...

New developments in lipid management

New developments in lipid management

  • pasty-toler
  • 0 Slides

CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP....

PCSK-9 Inhibitors Paul J

PCSK-9 Inhibitors Paul J

  • tatyana-admore
  • 52 Slides

PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...

Protecting the heart and the kidney:

Protecting the heart and the kidney:

  • pressio
  • 38 Slides

Implications from the SHARP trial. Dr. Christina R...

LDL Cholesterol Lowering with

LDL Cholesterol Lowering with

  • shoffer
  • 18 Slides

Evolocumab. and Outcomes in Patients with . Perip...

Diabetic dyslipidemia : The pro-

Diabetic dyslipidemia : The pro-

  • deborah
  • 47 Slides

atherogenic. role of CETP and future use of CETP ...

CETP inhibition : Where

CETP inhibition : Where

  • rodriguez
  • 21 Slides

are we . now. ?. Prof. John Kastelein. Academic. ...

The Placebo Drift Debate in Antidepressant Clinical Trials

The Placebo Drift Debate in Antidepressant Clinical Trials

  • celsa-spraggs
  • 8 Slides

Zach Daniel White. Biology 101h- . Desaix. Why do...

Does Meditation Really Work or It’s Placebo effect

Does Meditation Really Work or It’s Placebo effect

  • ellena-manuel
  • 13 Slides

Simge ALTINKÖK. Outline. Definition of meditati...

The Placebo Effect

The Placebo Effect

  • danika-pritchard
  • 11 Slides

. ...

What Accounts for Placebo Group

What Accounts for Placebo Group

  • alida-meadow
  • 19 Slides

Improvements and Can They Be Reduced?. John T. Fa...

The Placebo Effect

The Placebo Effect

  • alexa-scheidler
  • 57 Slides

Homeopathy. In the late 1700’s a German doctor ...

Anxiolytic Placebo Response in Outbred Mice

Anxiolytic Placebo Response in Outbred Mice

  • natalia-silvester
  • 1 Slides

Kelsey I. . Landaverde. , Stacey L. . Kirkpatrick...

Causal diagrams, the placebo effect, and the expectation effect

Causal diagrams, the placebo effect, and the expectation effect

  • ellena-manuel
  • 0 Slides

Eyal Shahar, MD, MPH. Professor. (. c. redit to D...

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular

  • mitsue-stanley
  • 14 Slides

ASCEND Randomized placebo-controlled trial of as...

Neratinib / Placebo treatment

Neratinib / Placebo treatment

  • heartersh
  • 8 Slides

0. 3. 6. 9. 12. 15. 18. 21. 24. Disease-free survi...

Alpha Omega MACE: 14.0% with EPA-DHA vs. 13.8% with placebo (p = 0.93)

Alpha Omega MACE: 14.0% with EPA-DHA vs. 13.8% with placebo (p = 0.93)

  • delcy
  • 1 Slides

MACE: 13.2% with ALA vs. 14.5% with placebo (p = 0...

Placebo (n = 2,333) Empaglifozin

Placebo (n = 2,333) Empaglifozin

  • SugarPlumFairy
  • 1 Slides

(. n . = 4,687). EMPA-REG OUTCOME. Primary . outco...

Fludrocortisone does not reduce the risk of recurrent syncope at 12 months compared with placebo i

Fludrocortisone does not reduce the risk of recurrent syncope at 12 months compared with placebo i

  • delcy
  • 1 Slides

syncope. Given the trend towards benefit though, i...

Placebo (n = 38) Metoprolol

Placebo (n = 38) Metoprolol

  • unita
  • 1 Slides

(. n . = 37). Metoprolol for AR. Primary endpoint,...

New Insights in

New Insights in

  • yoshiko-marsland
  • 12 Slides

the Understanding . of . Cholesterol Metabolism:....

Cholesterol and C.V.D.

Cholesterol and C.V.D.

  • sherrill-nordquist
  • 12 Slides

Learning outcome. Most cholesterol is synthesised...

Genetic Variants of Proprotein Convertase Subtilisin/Kexin

Genetic Variants of Proprotein Convertase Subtilisin/Kexin

  • mitsue-stanley
  • 17 Slides

Type 9 (PCSK9). Implications for Low-Density Lipo...

DIABETES AND LIPID

DIABETES AND LIPID

  • yoshiko-marsland
  • 93 Slides

S-KHALILZADEH. Lipids are hydrophobic molecules t...

Copyright © 2024 DocSlides. All Rights Reserved